21 March 2017Pharma

Video interview: Taylor Wessing on SPCs at the CJEU

There have been two significant references on issues that have been "left hanging" by the Court of Justice of the European Union (CJEU) in the last spate of decisions, says Paul England, senior associate at Taylor Wessing, in a video interview with LSIPR.  England discusses the two important references to the CJEU with regard to supplementary protection certificates.  Here he covers the Teva v Gilead Sciences and Abraxis Bioscience references, and talks about the importance of these cases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
15 October 2026   A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.
Pharma
14 October 2026   Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.
Pharma
13 October 2026   Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.